Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?
Theocharis KoufakisSymeon MetallidisPantelis ZebekakisRamzi A AjjanKalliopi KotsaPublished in: Journal of diabetes science and technology (2020)
Keyphrases